Multiple Myeloma News
Oncopeptides will seek accelerated approval from the FDA after melflufen demonstrates a manageable safety profile.
Patients with multiple myeloma on dialysis who are undergoing autologous stem cell transplantation are at an increased risk for inpatient mortality.
Previously conducted retrospective studies may have underestimated the incidence of hydroxyurea-related skin toxicity in patients with MPNs.
Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.
The FDA issued a clinical hold for a trial evaluating a universal CAR T-cell product in patients with relapsed or refractory multiple myeloma after 1 patient died.
New research presented at ASCO 2020 sheds light on conflicts of interest among NCCN panelists and links industry dollars to measures of academic success among junior faculty.
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
Matched cohort study showed risk greatest for those with primary myelofibrosis, but still high for those with polycythemia vera and essential thrombocythemia.
For patients with initial myeloma cast nephropathy, renal response rates did not significantly vary after doublet vs triplet bortezomib-based treatments.
The administration of cedazuridine with decitabine prevents the degradation of decitabine by CDA in the gastrointestinal tract and liver increasing its systemic exposure.
An assay from Mayo Clinic researchers screens multiple myeloma drugs to see how cells with different biomarkers and pretreatment histories react.
The majority of patients enrolled in this phase 3 trial had previously received both a proteasome inhibitor and an immunomodulatory agent.
Despite thromboprophylaxis, patients who have newly developed multiple myeloma are at an “unacceptably high VTE risk”, study results suggest.
Ixazomib maintenance therapy prolonged PFS compared with placebo among patients with newly diagnosed MM who were not eligible for transplant.
Ruxolitinib discontinuation syndrome was associated with spleen length and platelet count, although severe cases were rare in a cohort of patients with myelofibrosis.
Ixazomib, lenalidomide, and dexamethasone are all oral agents and each one has been approved by the FDA in the setting of multiple myeloma.
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Enrichment of an early memory CD8+ T-cell phenotype in patients’ blood was predictive of their response to CAR-T therapy in CLL, NHL, and MM.
Researchers presented initial results from an ongoing, phase 3, randomized study of once-weekly SVd vs twice-weekly Vd after 1 to 3 prior anti-multiple myeloma regimens.
Carfilzomib plus lenalidomide and dexamethasone failed to improve outcomes compared with bortezomib plus lenalidomide and dexamethasone among patients with newly-diagnosed MM.